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Prematurity is a major risk factor for intraventricular haemorrhage (IVH). Premature infants 
often require respiratory support. There is little information on neonates with IVH who 
require respiratory support in low and middle income countries. 
 
Objective 
To describe the characteristics and short-term outcomes of very low birth weight (VLBW) 




This was a matched retrospective observational study. The population included VLBW 
infants with IVH, who received positive pressure respiratory support between January 2014 
and December 2016. Outcomes of infants with severe IVH was compared to those with mild 
IVH. Outcomes were further analysed according to mode of ventilation. 
 
Results 
150 infants were included in the study, 56 (37%) received continuous positive airway 
pressure (CPAP) only and 94 (63%) mechanical ventilation. Severe IVH was associated with 
surfactant therapy across both ventilation groups (p=0.03). Oxygen requirement at 28 days 
was more frequent in infants with severe IVH compared to mild IVH (79% vs 38%, p=0.01) 
(OR 6.11 (95% CI 1.19-31.34), p=0.03). Severe IVH and the presence of coagulopathy were 
the strongest predictors of death in both ventilation groups (p <0.0001). Pulmonary 
haemorrhage was the commonest cause of death in those with severe IVH and blood culture 
confirmed sepsis in those with mild IVH. Periventricular leukomalacia (PVL) was associated 
with severe IVH in those receiving invasive ventilation (OR 6.67 (95% CI 1.11-40.17)). 
 
Conclusion 
Mechanical ventilation, coagulopathy and pulmonary haemorrhage were strongly associated 
with death in VLBW infants with severe IVH in a resource-limited setting. These prognostic 
factors may have a role in end of life decisions. 
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INTRODUCTION AND LITERATURE REVIEW 
INTRODUCTION 
Intraventricular haemorrhage (IVH) is a common complication in preterm infants. The 
relationship has been well described with the incidence increasing with decreasing gestational 
age.[1-3] This differs to IVH in term infants, which is due to a different pathophysiology with 
bleeding in areas other than the germinal matrix.[4] 
 
The periventricular germinal matrix is a highly vascularized region which is vulnerable to 
bleeding in the preterm infant.[1,2] Involution begins at 28 weeks gestation and is usually 
complete by 36 weeks, after which the risk of bleeding is minimal.[5] Multiple factors can 
injure this fragile area of the brain leading to IVH.[3] These factors lead to injury by causing 
disturbances in the cerebral blood flow.[1,2] Fluctuations in cerebral blood flow alters the 
brain’s ability to maintain cerebral autoregulation, a process likely already compromised 
based on the severity of the prematurity and the stability of the infant.[1,2] 
 
Cranial ultrasonography allows for rapid diagnosis and grading of IVH.[3] Volpe adapted 
Papile’s original grading system to create the following widely used classification [6,7]: 
 
Grade 1 – Germinal matrix haemorrhage and/or IVH <10% of ventricle 
Grade 2 – Germinal matrix haemorrhage and IVH 10-50% of ventricle 
Grade 3 – Germinal matrix haemorrhage and IVH involving more than 50% of ventricle 
(often with distended lateral ventricles) 
Grade 4 – Periventricular haemorrhagic infarction, cystic periventricular leukomalacia (PVL) 
 
Grading IVH is important in determining prognosis. Mild IVH refers to grade 1 and 2, severe 





1. To assess the common risk factors associated with intraventricular haemorrhage in 
preterm infants 
2. To assess the complications and outcomes associated with intraventricular 
haemorrhage in preterm infants 
 
LITERATURE SEARCH 
An online search was done on Pubmed to review the literature from the year 2000 onwards. 
The literature review was conducted during 2016 with the intention of researching evidence 
over the last 15 years. 
 
Search terms: 
1. (("Infant, Premature"[Mesh]) OR "Infant, Premature, Diseases"[Mesh]) AND ((( 
"Intracranial Hemorrhages/etiology"[Mesh] OR "Intracranial Hemorrhages/prevention 
and control"[Mesh] )) OR ( "Cerebral Hemorrhage/etiology"[Mesh] OR "Cerebral 






This search yielded 625 results, of which 72 articles were relevant to the objectives of 
this study. 57 clinical trials were available and comprise the risk factors analysis for 
this literature review. 
 
2. (("Infant, Premature"[Mesh]) OR "Infant, Premature, Diseases"[Mesh]) AND 








This search yielded 220 results of which 29 articles were relevant to the objectives of 






IVH has been extensively studied to determine potential means of either preventing the 
incidence or worsening of this condition. 57 studies were reviewed with a summary of the 
findings presented in table 1. 
 
Prematurity is the most important risk factor for developing IVH.[1-2] The best way to prevent 
IVH is to prevent factors that lead to preterm labour and delivery. 
 
Multiple trials have confirmed the recognised benefits of antenatal corticosteroids in reducing 
the incidence of IVH.[8-13] This is achieved by stabilizing blood vessels in the germinal matrix 
and maintaining cerebral blood flow. In addition, antenatal steroids reduce respiratory 
distress syndrome (RDS), a disease process which contributes to cerebral blood flow 
fluctuations.[1] 
 
Partial or complete treatment with steroids showed improved mortality outcomes and lower 
rates of severe IVH compared to no treatment.[13] A single dose in preterm rupture of 
membranes was shown to decrease the incidence of severe IVH.[13] Both betamethasone and 
dexamethasone reduce the risk of IVH and severe IVH.[8,9]  
 
Chorioamnionitis is a risk factor for preterm delivery and the associated complications 
thereafter. It has been well described as a risk factor for IVH, even when adjusting for 
gestational age.[14-17] Steroids have been shown to be beneficial in decreasing IVH in the 
presence of chorioamnionitis.[18] 
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More evidence is emerging showing a strong association between transportation of extreme 
preterm infants and IVH.[19,20] High risk mothers should ideally be delivered in a tertiary 
neonatal unit where early stabilisation of the infant may prevent IVH. 
 
While a multicentre prospective cohort showed caesarean section delivery as protective 
against IVH,[21] further studies found no difference in outcome depending on mode of 
delivery and IVH.[22,23]  
 
Maternal HELLP syndrome (haemolysis, elevated liver enzymes, low platelets) was 
associated with an increased incidence of severe IVH in preterm infants.[24] Antenatal 
magnesium sulphate showed improved long term neurological outcomes but has had no effect 
on IVH.[25] 
 
Delayed cord clamping (along with the benefits of improved mortality, reduced anaemia and 
reduced incidence of necrotizing enterocolitis (NEC)) has shown to be protective against IVH 
across all grades and is generally recommended for vigorous preterm infants not requiring 
resuscitation.[25-28] 
 
Reducing blood transfusions in the first week of life may be associated with a decreased 
incidence of IVH.[29.30] The association is unclear given that the clinical factors that lead to 
early blood transfusions may be relevant to the cause of IVH in these infants.[29] 
 
The role of coagulopathy in the pathogenesis of IVH is not clearly demonstrated. However it 
does influence the risk and severity of the condition. Several treatment strategies have been 
reviewed.[31-37] 
 
The use of anticoagulants to prevent the formation of thrombi (implicated as a possible cause 
of IVH) does not show any clear benefit.[31] Systematic reviews done by Bruschettini et al. 
found insufficient evidence to recommend treatment with heparin or antithrombin.[32,33] Fresh 
frozen plasma (FFP) transfusions are not recommended prophylactically.[34,35] Dani et al. 
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demonstrated that coagulopathy screening and empiric treatment with FFPs reduced the risk 
of IVH only in 23-26 week gestation infants.[34] Tran et al. was able to identify preterm 
infants at risk for coagulopathy and severe IVH but FFPs were not beneficial in preventing 
IVH or decreasing mortality.[35] Prophylactic administration of Factor VII did not 
demonstrate any clear benefits in reducing IVH in a small prospective study.[36] Antenatal 
vitamin K did not reduce the incidence of IVH in preterm infants.[37] 
 
The incidence and severity of IVH was not influenced by platelet transfusions. 
Thrombocytopaenia can be found in IVH, but the severity of the thrombocytopaenia does not 
compare with the grade of IVH.[38] Platelet transfusions did not influence the incidence of 
IVH.[39] Ethamsylate was considered due to its ability to promote platelet adhesiveness. A 
systematic review showed a decrease in severe IVH in infants <35weeks but did not affect 
infants <32 weeks. It does not reduce mortality or affect neurodevelopment and is not 
recommended for routine use.[40] 
 
Patent ductus arteriosus (PDA) causes variations in cerebral blood flow and is a risk factor 
for IVH.[1] The role of indomethacin and ibuprofen has been reviewed in preventing this 
phenomenon. Indomethacin has a role in treating infants with symptomatic PDAs. It reduces 
severe IVH in the short term by creating vascular stability.[1-3] This has been demonstrated in 
several studies.[41-44] However, it does not provide any long term protection against 
neurodevelopmental outcomes and has no effect on mortality.[41,42] Ibuprofen does not 
influence cerebral blood flow and therefore has no effect on IVH.[1] This was demonstrated in 
several randomised controlled trials in infants who received prophylactic ibuprofen.[45-46] 
 
The mechanism of action of phenobarbital in stabilisation of blood pressure was postulated to 
potentially prevent IVH. A meta-analysis of twelve randomised control trials showed no 
effect of postnatal phenobarbital on prevention of IVH with an increased requirement for 
mechanical ventilation due to the sedative effects of phenobarbital.[47] Antenatal 
phenobarbital has also been reviewed with no benefits demonstrated.[48] 
 
Hypothermia failed to show a strong association with IVH in the studies reviewed.[49,50] 
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Hypernatraemia, a complication of extremely low birth weight (ELBW), leads to vascular 
rupture and is associated with IVH.[51] 
 
A large randomized control trial by Fauchère, showed no difference in IVH in infants given 
erythropoietin.[52] 
 
Respiratory distress, acidosis, asphyxia and hypoxia all affect cerebral blood flow and are 
associated with an increased incidence of IVH.[53-55] Both hypercapnia and hypocapnia are 
associated with severe IVH.[56-58] Pneumothorax increases cerebral venous pressure and can 
influence the progression of IVH.[59] 
 
Prophylactic surfactant was an independent protective factor in reducing IVH overall 
compared to rescue treatment when analysed across three randomized controlled trials.[60] A 
2012 meta-analysis showed an overall marginal decrease in IVH in patients receiving 
prophylactic surfactant in comparison to selective surfactant treatment.[61] 
 
Mechanical ventilation has significant hemodynamic effects on the infant which could affect 
cerebral blood flow.[1] Prolonged positive pressure ventilation also increases the blood brain 
barrier permeability and contributes to the development of IVH.[1] The SUPPORT study 
compared infants who received CPAP versus intubation with surfactant in the delivery room. 
There was no difference in IVH between the two groups.[62] Early and prolonged mechanical 
ventilation are important predictors for severe IVH.[54,63] Pancuronium use in infants to 
achieve better control of mechanical ventilation, has shown a decrease in the incidence of 





Table 1: Summary of Risk factors of IVH 
  
























dexamethasone and the 
effects on neonatal morbidity 
and mortality 
Reduction in IVH with both 
agents, but more so with 
dexamethasone 
2 Lee et al [9] 
Adverse neonatal 











dexamethasone and the 
effects on neonatal morbidity 
and mortality 
Reduction in severe IVH in 
both groups, with a lower 









outcomes and neonatal 
morbidities of extremely 
premature infants with 









Comparison of outcomes of 
no, partial or complete 
antenatal steroids in preterm 
infants 
Both partial and complete 
antenatal steroids was 
associated with a decrease in 
severe IVH compared to no 
antenatal steroids 
4 
Maksić et al 
[11] 
The effects of antenatal 











The effects of antenatal 
corticosteroids on the 
incidence of IVH 
Decreased incidence of IVH 
in infants who received 
antenatal steroids 
5 Wei et al [12] 
Impact of antenatal 
steroids on intraventricular 
hemorrhage in very-low-







The effects of antenatal 
steroids in preventing IVH 
Antenatal steroids are 
strongly associated with a 







Effectiveness of antenatal 
corticosteroid 
administration after 
preterm premature rupture 






The effect of antenatal 
betamethasone on preterm 
morbidities in preterm 
premature rupture of 
membranes 
Antenatal betamethasone 
given in preterm premature 
rupture of membranes is 
associated with a reduced risk 
of severe IVH 
Chorioamnionitis 
1 Ahn et al [14] 
The association of 
histological 
chorioamnionitis and 
antenatal steroids on 
neonatal outcome in 
preterm infants born at less 







Assess the effects of 
chorioamnionitis on neonatal 
morbidities 
Higher incidence of severe 
IVH with chorioamnionitis 
2 
De Felice et 
al [15] 








Determine neonatal outcomes 
in clinical and histological 
chorioamnionitis 
Significant association with 
IVH in histological 
chorioamnionitis, 





Mehta et al 
[16] 







Determine neonatal outcomes 
in preterm infants with 
placental pathology and its 
association with gestational 
age 
Placental pathology is 
associated with an increased 





Association of histologic 
chorioamnionitis, 
increased levels of cord 
blood cytokines, and 
intracerebral hemorrhage 














The effects of antenatal 
corticosteroids therapy on 








Assess neonatal outcomes 
following antenatal steroids 
in histological 
chorioamnionitis 
Antenatal steroids was 
associated with reduced 
incidence of IVH 
Transport 
1 
Köksal et al 
[19] 
Risk factors for 
intraventricular 
haemorrhage in very low 






To assess the risk factors 
associated with IVH in 
preterm infants 
Postnatal transport of infants 
to tertiary hospitals was 
associated with an increased 






Transport of premature 
infants is associated with 








The association of neonatal 
inter-hospital transport on the 
incidence and severity of 
IVH. 
Inter-hospital transport of 
neonates is associated with an 
increased incidence and 
increased severity of IVH 
Mode of delivery 
1 
Helwich et al 
[21] 
Intraventricular 
hemorrhage in premature 
infants with Respiratory 
Distress Syndrome treated 
with surfactant: incidence 
and risk factors in the 






Assess risk factors for IVH in 
preterm infants with 
respiratory distress syndrome 
treated with surfactant 
Caesarean section was 
protective against IVH in 
preterm infants 
2 
Ljuština et al 
[22] 
Analysis of intracranial 
hemorrhage grade in 
preterm singleton 
pregnancies delivered 







To compare mode of delivery 
with IVH 
No significant difference 
demonstrated between mode 





Werner et al 
[23] 
Mode of delivery and 








To assess mode of delivery 
on preterm neonatal outcomes 
No difference in IVH 
between mode of delivery 
HELLP syndrome 
1 Kim et al [24] 
Neonatal outcome after 







Assess outcomes of preterm 
neonates in HELLP syndrome 
and severe preeclampsia 
Increased incidence of severe 







for babies of antenatal 
magnesium sulphate: An 










Determine effects and 
outcomes of antenatal 
magnesium sulphate on 
preterm neonates  
 Neuroprotective effect 
with decreased incidence 
of cerebral palsy 








Effect of delayed cord 









The assess the effects of 
delayed cord clamping on 
IVH in preterm infants 
Delayed cord clamping 
decreases the incidence of 
IVH in preterm infants 
2 
Mercer et al 
[27] 
Delayed cord clamping in 
very preterm infants 
reduces the incidence of 
intraventricular 
hemorrhage and late-onset 








Comparison of neonatal 
outcomes between immediate 
and delayed cord clamping in 
preterm infants  
Delayed cord clamping 
decreases the incidence of 
IVH in preterm infants 
3 Rabe et al [28] 
Effect of timing of 
umbilical cord clamping 
and other strategies to 
influence placental 
transfusion at preterm 










Comparison of neonatal 
outcomes with delayed cord 
clamping compared to early 
cord clamping 
Reduced incidence of IVH 
with delayed cord clamping 








et al [29] 
Association, among very‐
low‐birthweight neonates, 
between red blood cell 
transfusions in the week 









The effects of reduced early 
red blood cell transfusions on 
the incidence of IVH  
 Decreased incidence of 
severe IVH since 
reducing early RBC 
transfusions in a 
neonatal intensive care 
unit (NICU). 
 Association is unclear 
2 
Hasanbegovi
c et al [30] 
Evaluation and treatment 







Assess the frequency of 
anaemia in preterm infants in 
a neonatal unit and the need 
for blood transfusions 
Anaemia was more frequent 
in infants < 32 weeks’ 
gestational age, who required 
blood 
transfusions more often 
Coagulopathy 
1 Fulia et al [31] 
Can the Administration of 
Antithrombin III Decrease 
the Risk of Cerebral 








To assess if antithrombin 
given prophylactically to 
preterm infants decreases the 
risk of IVH 
Antithrombin did not 






et al [32] 
Heparin for the prevention 
of intraventricular 










To assess if heparin given 
prophylactically to preterm 
infants decreases the risk of 
IVH 
Heparin did not decrease the 
incidence of IVH 
3 
Bruschettini 
et al [33] 
Antithrombin for the 
prevention of 
intraventricular 










To assess if antithrombin 
given prophylactically to 
preterm infants decreases the 
risk of IVH 
Antithrombin did not 
decrease the incidence of IVH 
4 Dani et al [34] 
Coagulopathy screening 
and early plasma treatment 
for the prevention of 
intraventricular 







To assess the effects of early 
FFP treatment, in preterm 
infants with coagulopathy, on 
IVH 
Coagulopathy screening and 
early FFPs were beneficial in 
reducing IVH in infants < 23-















To assess the effects of early 
FFP treatment  on IVH, in 
preterm infants with 
abnormal coagulation screens 
 Screening identified high 
risk neonates at risk for 
IVH 
 FFPs to correct 
coagulopathy did not 





A prospective pilot study 
of prophylactic treatment 
of preterm neonates with 
recombinant activated 
factor VII during the first 






To assess the effects of 
prophylactic factor VII on 
preterm infants 
 Small sample size 





Vitamin K prior to preterm 











To assess the effects of 
antenatal vitamin K on 
neonatal morbidity and 
mortality 
No difference noted in the 
incidence of IVH with 






et al [38] 
Thrombocytopaenia and 
intraventricular 
haemorrhage in very 







To assess the effects of 
platelet transfusions on IVH  
in preterm neonates with 
thrombocytopaenia 
Platelet transfusions in 
asymptomatic neonates with a 
count of <30 x 109/l did not 
reduce the incidence of IVH 
9 










To assess platelet transfusions 
in preterm neonates with 
thrombocytopaenia and its 
risk on IVH 
 Transfusion depended 
on severity of illness 
 Thrombocytopaenia did 
have a higher risk of 
IVH, but was not 
dependant on the actual 
platelet count 
 Platelet transfusions did 





10 Hunt et al [40] 
Ethamsylate for the 
prevention of morbidity 
and mortality in preterm or 











Prophylactic ethamsylate in 
preterm infants and its effects 
on neonatal outcomes 
 Reduced severe 
IVH in infants < 35 
weeks’ gestational age, 
but not in infants < 32 
weeks’ gestational age 




Indomethacin and Ibuprofen 
1 




preventing mortality and 










To assess the effects of 
prophylactic indomethacin in 
preterm infants, on morbidity 
and mortality 
 Decreased incidence in 
IVH and PDAs 
 No difference in 







Schmidt et al 
[42] 










To assess the effects of 
prophylactic indomethacin in 
preterm infants, on morbidity 
and mortality 
 Decreased incidence in 
IVH 
 No difference in 






The use of indomethacin 
for the prevention of 
intraventricular brain 







To assess the effects of 
prophylactic indomethacin on 
the incidence of IVH 







reduces grades III and IV 
intraventricular 
hemorrhages when 
compared to early 
indomethacin treatment of 







To assess the effects of 
prophylactic indomethacin on 
the incidence of severe IVH  
Decreased incidence in severe 





5 Dani et al [45] 
Prophylactic ibuprofen for 
the prevention of 
intraventricular 
hemorrhage among 









To assess the effects of 
prophylactic ibuprofen on the 
incidence of IVH grade 2-4 
There was no difference in 






Prophylactic ibuprofen in 










To assess the effects of 
prophylactic ibuprofen on the 
incidence of severe IVH 
 No effect on severe IVH 






1 Smit et al [47] 
Postnatal phenobarbital for 
the prevention of 
intraventricular 











Prophylactic phenobarbital in 
preterm infants and its effects 
on neonatal outcomes 
 Does not reduce the 
incidence of IVH 





Phenobarbital prior to 













phenobarbital and its effects 
on preterm IVH 
 Does not reduce the 
incidence of IVH 




Audeh et al 
[49] 
Does admission 










To assess admission 
hypothermia as a risk factor 
for IVH in preterm infants 
Admission hypothermia was 






Miller et al 
[50] 
Hypothermia in very low 
birth weight infants: 







To assess the outcomes of 
preterm neonatal hypothermia 
Babies with moderate 
hypothermia had an increased 
odds of developing IVH 
Hypernatraemia 
1 
Dalton et al 
[51] 
Assessment of association 
between rapid fluctuations 











To determine the association 
between serum fluctuations in 
sodium and IVH 
Hypernatraemia in preterm 





Safety of early high-dose 
recombinant 
erythropoietin for 








To assess the neuroprotective 
effects of prophylactic 
erythropoietin 
There was no difference in 





1 Ertan et al [53] 
Perinatal risk factors for 
neonatal intracerebral 







To assess the risk factors 
associated with IVH in 
preterm infants 
Acidosis, low APGARS and 
thrombocytopaenia was 
associated with IVH 
2 
Helwich et al 
[54] 
Intraventricular 
hemorrhage in premature 
infants with Respiratory 
Distress Syndrome treated 
with surfactant: incidence 
and risk factors in the 






To assess  IVH in preterm 
infants with RDS treated with 
surfactant 
 Significant incidence of 
IVH in RDS 
 Mechanical ventilation 
was the strongest risk 









inflammation is related to 
early but not late 
peri/intraventricular 







To determine if cytokine 
levels in infants with RDS are 
associated with the 
development of early IVH-
PVH within the first 12 hours 
of life in contrast to IVH-
PVH developing after 12 
hours of life 
Association between RDS 
and developing IVH 
demonstrated by raised 
cytokine levels 
4 
Fabres et al 
[56] 
Both extremes of arterial 
carbon dioxide pressure 
and the magnitude of 
fluctuations in arterial 
carbon dioxide pressure 
are associated with severe 
intraventricular 







To assess hypocapnia and 
hypercapnia in preterm 
infants in the first 4 days of 
life and its association with 
severe IVH 
Hypocapnia and hypercapnia 
is associated with severe IVH 





Erickson et al 
[57] 
Hypocarbia in the 
ventilated preterm infant 










To assess CO2 levels in 
ventilated preterm infants and 
severe IVH 
Hypocapnia is associated with 
severe IVH in ventilated 
preterm infants 
6 
Kaiser et al 
[58] 
Hypercapnia during the 
first 3 days of life is 
associated with severe 
intraventricular 
hemorrhage in very low 






To assess hypercapnia as a 
risk factor for severe IVH in 
preterm infants during first 3 
days of life 
Hypercapnia is associated 
with an increased risk of 
severe IVH in preterm infants 
7 
Pishva et al 
[59] 
Intraventricular 
hemorrhage in premature 








To assess pneumothorax as a 
risk factor for IVH 
 Pneumothorax 
aggravates IVH in 
preterm infants 
 Pneumothorax is a risk 






1 Walti et al [60] 
Prophylactic 
administration of porcine-
derived lung surfactant is a 
significant factor in 
reducing the odds for peri-
intraventricular 









risk of RDS 
Comparison of prophylactic 
surfactant to rescue surfactant 
in reducing the rate of IVH 
Prophylactic surfactant in 
preterm infants with RDS is 
an independent protective 
factor against IVH 
2 
Rojas‐Reyes 
et al [61] 
Prophylactic versus 
selective use of surfactant 
in preventing morbidity 











Comparison of outcomes of 
prophylactic surfactant to 
selective surfactant in RDS 
preterm infants 
 Decreased risk of IVH 
with prophylactic 
surfactant compared 
with early CPAP and 
selective surfactant 
 Trend towards 
decreased risk of severe 
IVH with prophylactic 
surfactant compared 









Early CPAP versus 








Comparison of CPAP to 
surfactant and ventilation in 
preterm infants 
No difference in IVH 
between the two groups 
2 Aly et al [63] 
Is mechanical ventilation 
associated with 
intraventricular 







The association between 
mechanical ventilation and 
IVH in preterm infants 
Early and prolonged 
mechanical ventilation is 
associated with severe IVH 
3 
Cools et al 
[64] 
Neuromuscular paralysis 










Determine the effects of 
neuromuscular paralysis in 
mechanical ventilation 
 Decreased risk of IVH 
noted 






IVH is associated with multiple significant short and long term complications. 18 studies 
were reviewed with a summary of the findings presented in table 2. 
 
IVH causes brain injury through both primary and secondary mechanisms. The mass effect of 
blood in the ventricles leads to stretching of the ventricles and cellular damage (although the 
level of damage is unclear). Raised intracranial pressure may occur as a late complication due 
to the skull flexibility of the neonate. Finally, impaired reabsorption of the cerebrospinal fluid 
(CSF) due to inflammation of the subarachnoid villi, may cause a communicating 
hydrocephalus. [65,66] 
 
Secondary damage occurs from the effects of red blood cell lysis causing toxic effects on the 
cells of the brain and choroid plexus. Activation of the coagulation system leads to an 
inflammatory response and thrombus formation. Thrombus formation causes obstruction of 
the ventricular system leading to a non-communicating hydrocephalus.[65,66] 
 
Mortality increases as the severity of IVH progresses, with grade 4 IVH having the worst 
prognosis.[67,68] 
 
Several studies have supported the notion that mild IVH is associated with normal 
neurological outcomes.[69.70] This is being continually studied.  Magnetic resonance imaging 
(MRI) scans on preterm infants with mild IVH found a reduction in cerebral volume in this 
referenced prospective cohort analysis.[71] A meta-analysis comprising 9 studies, assessing 
the long term outcomes of IVH found mild IVH was associated with some neurological 
impairment, but not cerebral palsy, compared to no IVH.[68] The impact of severe IVH has 
been clear; neurodevelopmental outcomes are worse with increasing severity.[72]  
 
Post haemorrhagic hydrocephalus (PHH) is a severe complication of IVH with important 
complications. Hydrocephalus affects the white matter of the brain and impairs brain 
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growth.[73] It has a direct link with the severity of the grade of IVH.[74] It also has a strong 
association with poor neurological outcomes.[75] 
 
Increasing severity of IVH is a risk factor for ventriculoperitoneal (VP) shunts in PHH.[76] 
Infants who require VP shunts have poorer neurological outcomes and higher mortality rates 
than infants who don’t require shunts.[75-77] 
 
Removal of CSF by repeat lumbar punctures does not improve outcomes in comparison to 
conservative treatment, or reduce the need for surgical shunts.[78,79] Thrombolytics, 
acetazolamine and furosemide also do not reduce the need for surgical shunts to treat 
hydrocephalus.[79,80] 
 
If there is progressive dilatation, surgical management of PHH includes external ventricular 
drainage (EVD) as a temporary measure. Early placement with stabilization of intracranial 
pressure is associated with better outcomes.[79] Ventricular access devices/reservoirs is 
another temporizing measure which allows for easier withdrawal of CSF than serial lumbar 
punctures (LP), although have a higher incidence of needing a permanent VP shunt compared 
to EVD.[79] 
 
White matter injury and the formation of cystic PVL are complications from severe IVH. [81] 
White matter injury can occur from ventricular enlargement and compression on surrounding 
brain tissue. The resulting effect is inflammation and further injury.[81] The immaturity of the 
vascular system of the brain also predisposes it to ischaemic injury.  [3] Brain parenchyma is 
also vulnerable to oxygen free radicals which occur during ischemia. This leads to 
periventricular focal necrosis and cyst formation, which usually occurs 2-3 weeks post 
injury.[81] 
 
Cystic PVL is associated with significant outcomes of severe neurological impairment and 
cerebral palsy. The risk of cystic PVL increases in grade 3 and 4 IVH.[82] 
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There is no clear relationship between retinopathy of prematurity (ROP) and IVH.  A small 
cross sectional study looking at ocular outcomes, found severe IVH to be associated with 
worse ROP than mild IVH.[83] A study by Watts et al. showed no association between severe 
IVH and severe ROP; the majority of infants with stage 3 ROP had grade 1 IVH.[84] Optic 




Table 2: Summary of Outcomes of IVH 





1 Radic et al [67] 
Outcomes of intraventricular 
haemorrhage and post 
haemorrhagic hydrocephalus 
in a population-based cohort 
of very preterm infants born 
to residents of Nova Scotia 





Analyse outcomes of 
IVH in preterm infants 
 Mortality increased with 
severity of IVH 
 Grade 4 IVH associated 
with cerebral palsy 
2 
Mukerji et al 
[68] 
Periventricular/Intra- 











outcomes in preterm 
infants with IVH 
 Severe IVH is 
associated with poorer 
outcomes compared to 
mild and no IVH 
 Mild IVH associated 
with neurological 







Reubsaet et al 
[69] 














outcomes in preterm 
infants with mild IVH 
compared to no IVH 
Outcomes were similar in 
both groups 
2 Wy et al [70] 
Impact of intraventricular 
hemorrhage on cognitive and 
behavioral outcomes at 18 
years of age in low birth 







To determine the effect 
of mild IVH on 
intellectual and 
behavioural function 
Mild IVH was not a risk 






intraventricular hemorrhage is 
followed by reduced cortical 






To assess cortical 
development following 
uncomplicated IVH 
MRI scans demonstrated a 
reduction in cerebral cortical 
grey matter in infants with 







Schrehof et al 
[72] 












outcomes in different 
grades of IVH in 
preterm infants 
 Neurological 
impairment occurred in 
all grades of IVH 
 Worse outcomes with 
increased severity of 
IVH 
Post haemorrhagic hydrocephalus 
1 Jary et al [73] 
Impaired brain growth and 
neurodevelopment in preterm 







To correlate MRI scans 
in preterm infants 
closer to term with 
neurodevelopmental 
outcomes at 2 years 
 Preterm infants with 
post haemorrhagic 
ventricular dilatation 
had reduced brain 
volumes on MRI 
 Decreased brain 
volumes was strongly 






Sajjadian et al 
[74] 
Incidence of intraventricular 
hemorrhage and post 
haemorrhagic hydrocephalus 







To determine the 




with severity of IVH 
3 
Srinivasakuma
r et al [75] 
Post haemorrhagic ventricular 









outcomes of severe 
IVH with post 
haemorrhagic 
ventricular dilatation 
 Severe IVH with post 
haemorrhagic 
ventricular dilatation is 
associated with worse 
outcomes than severe 
IVH without post 
haemorrhagic 
ventricular dilatation 
 Outcomes were worse in 





4 Kazan et al [76] 
Hydrocephalus after 
intraventricular hemorrhage in 
preterm and low-birth weight 
infants: analysis of associated 






To assess risk factors 
for VP shunts in 
posthaemorrhagic 
hydrocephalus 
Severity of IVH is a risk 
factor for VP shunts 
5 
Christian et  
al [77] 
Trends in hospitalization of 
preterm infants with 
intraventricular hemorrhage 
and hydrocephalus in the 









Severity of IVH correlates 






Whitelaw et al 
[78] 
Repeated lumbar or 








To assess if repeated 
CSF removal in infants 
at risk of post 
haemorrhagic 
hydrocephalus, reduces 
the risk of permanent 
shunt, disability or 
death compared to 
conservative 
management 
Does not reduce placement of 
permanent shunt, risk of 
disability or mortality rates 
7 
Mazzola et al 
[79] 
Paediatric hydrocephalus: 
systematic literature review 
and evidence-based 
guidelines. Part 2: 
management of post 
haemorrhagic hydrocephalus 
in premature infants 
Systematic 




To assess the optimal 
treatment strategies for 
post haemorrhagic 
hydrocephalus 
Serial lumbar punctures, 
acetazolamide, furosemide 
and thrombolytics do not 
reduce the need for shunt 
placement 
Surgical temporizing 





















Streptokinase was not 
effective in reducing the need 
for shunt surgery 
Periventricular leukomalacia 
1 
Kusters et al 
[81] 
''Intraventricular'' hemorrhage 
and cystic periventricular 
leukomalacia in preterm 






To assess the 
association between 
grades of IVH and 
cystic PVL 
Increased incidence of cystic 








Ocular outcomes in low birth 







To assess ocular 
outcomes in preterm 
infants with IVH 
Infants with severe IVH were 
more likely to have stage 3 
retinopathy or higher 
2 Watts et al [84] 
Intraventricular haemorrhage 









To assess association 
between IVH and stage 
3 ROP 
 IVH was associated 
with stage 3 ROP 
 ROP was not dependent 
on severity of IVH 
3 
O'keefe et al 
[85] 
Ocular significance of 
intraventricular haemorrhage 








Comparison of ocular 
pathology in mild and 
severe IVH 
 All grades of IVH 
associated with reduced 
visual acuity 
 Optic atrophy is more 




Very low birth weight (VLBW) infants are vulnerable to complications associated with 
prematurity. There is on-going research to help develop strategies to improve these risks, 
especially for developing countries. 
 
The increased use of non-invasive ventilation and the practice of INSURE (intubation-
surfactant-extubation) has helped to improve respiratory complications and reduced the need 
for invasive ventilation, a scarce resource in developing countries. 
 
IVH is another significant complication in preterm infants. Severe IVH is strongly associated 
with increased mortality. It also leads to neurodevelopmental impairment, post haemorrhagic 
hydrocephalus and prolonged hospital admissions, which carry further risks and 
complications. Lifelong medical support is often needed comprising multidisciplinary teams. 
This places an additional strain on an already burdened healthcare system. 
 
Applying preventative measures such as antenatal steroids and delayed cord clamping are 
valuable in protecting against IVH. Identifying which risk factors are more common will 
assist in the management of high risk infants and resource allocations. Risk factors such as 
ventilation, blood transfusions, coagulopathy and hypothermia can be identified in a unit and 
targeted for improvement strategies. 
 
The majority of articles in this literature review are from developed settings. More research is 
needed applying to resource limited settings. In this study the risk factors and outcomes of 
IVH will be analysed in VLBW infants in a developing setting. Given the close association 
with respiratory complications in VLBW infant as well as its relation as a risk factor in IVH, 
infants requiring respiratory support will be part of the studied population. This comparison 
could provide important information on reduction strategies and appropriate application of 
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Prematurity is a major risk factor for intraventricular haemorrhage (IVH). Premature infants 
often require respiratory support. There is little information on neonates with IVH who 
require respiratory support in low and middle income countries. 
 
Objective 
To describe the characteristics and short-term outcomes of very low birth weight (VLBW) 




This was a matched retrospective observational study. The population included VLBW 
infants with IVH, who received positive pressure respiratory support between January 2014 
and December 2016. Outcomes of infants with severe IVH was compared to those with mild 
IVH. Outcomes were further analysed according to mode of ventilation. 
 
Results 
150 infants were included in the study, 56 (37%) received continuous positive airway 
pressure (CPAP) only and 94 (63%) mechanical ventilation. Severe IVH was associated with 
surfactant therapy across both ventilation groups (p=0.03). Oxygen requirement at 28 days 
was more frequent in infants with severe IVH compared to mild IVH (79% vs 38%, p=0.01) 
(OR 6.11 (95% CI 1.19-31.34), p=0.03). Severe IVH and the presence of coagulopathy were 
the strongest predictors of death in both ventilation groups (p <0.0001). Pulmonary 
haemorrhage was the commonest cause of death in those with severe IVH and blood culture 
confirmed sepsis in those with mild IVH. Periventricular leukomalacia (PVL) was associated 
with severe IVH in those receiving invasive ventilation (OR 6.67 (95% CI 1.11-40.17)). 
 
Conclusion 
Mechanical ventilation, coagulopathy and pulmonary haemorrhage were strongly associated 
with death in VLBW infants with severe IVH in a resource-limited setting. These prognostic 




Intraventricular haemorrhage (IVH) is a frequent complication in preterm infants.[1,2] Severe 
IVH (characterized as grade III and grade IV) is associated with a high incidence of 
mortality, significant morbidities and long-term neurological impairment.[3] The rate of IVH 
increases with decreasing gestational age, with prematurity being the most important risk 
factor as evidenced by multiple studies.[1,2,4] 
 
Respiratory support as a risk factor for IVH has shown conflicting reports. Randomised 
controlled trials have showed that the use of prophylactic continuous positive airway pressure 
(CPAP) in preterm infants at birth does not demonstrate a significant difference in the 
incidence of IVH compared to low flow nasal cannula/oxyhood[5,6] or mechanical ventilation 
at birth.[7-9] However, observational research suggests that mechanical ventilation is 
associated with an increase in IVH, with early and prolonged ventilation being important 
determinants for severe IVH.[10] 
 
Respiratory support is frequently required in preterm infants.[11] Published literature on the 
subject is mainly from resource rich settings, limiting the applicability in middle income and 
developing countries where a high burden of preterm births exists.[12] These settings would 




To describe the occurrence of IVH and short-term outcomes in very low birth weight 
(VLBW) infants receiving positive pressure respiratory support in a single tertiary centre in a 
middle income African country. 
 
METHODS 
This was a matched retrospective observational study. Groote Schuur Hospital (GSH) has an 
incidence of approximately 500 VLBW infants born per annum. The source population 
included VLBW neonates with IVH, requiring either CPAP (non-invasive) or mechanical 
ventilation (invasive) admitted to GSH between January 2014 and December 2016. Neonates 
with major congenital abnormalities or other severe comorbidities, such as congenital syphilis 
or congenital cytomegalovirus infection, were excluded from the study. From the eligible 
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infants all those with a diagnosis of severe IVH were chosen as cases. The remaining infants, 
all comprising of mild IVH (Grade 1 and 2), were allocated as comparative controls. Controls 
were individually matched to each case (1:1) within the following strata: (1) Birth weight 
category (750 g or less; >750 g to 1000 g; >1000 g to 1250 g; or >1250 g), (2) Type of 
respiratory support (non-invasive versus invasive) and (3) year of birth. The matching 
process therefore yielded two groups for comparison: (A) all infants with severe IVH and (B) 
matched infants with mild IVH. 
 
Data Collection 
Since mid-2013 details of all VLBW infants admitted to GSH have been retrospectively 
entered into the Vermont Oxford Network (VON) database. The database consists of clinical 
details from birth until discharge/death and was utilised as a source for patient characteristics 
and outcomes. Data were extracted from patients’ folders for additional information not 
available from the database. 
 
Clinical care in the neonatal unit 
Clinical decision making for VLBW infants was guided by evidence based standardized 
protocols, in keeping with the resource limited setting of this study. 
 
Mechanical ventilation was considered for infants with a birth weight of ≥ 800 g. Those with 
severe IVH were ineligible for starting mechanical ventilation. Surfactant use was limited to 
those on CPAP or mechanical ventilation with persistent fraction of inspired oxygen (FiO2) 
requirements above 30%. Cranial sonography was performed on all VLBW infants before 
day 3 of life, again at age 3-5 weeks and at discharge or corrected term gestation (depending 
on which came first). Scan frequency would be increased according to clinical condition. 




Descriptive statistics were used to summarize all relevant characteristics, using standard 
comparative methods. Data were analyzed for the full cohort and within strata of ventilation 




Potential risk factors for the outcomes of severe compared to mild IVH were evaluated, using 
a case-control approach. Data were analysed using crude and adjusted conditional logistic 
regression, controlling for matched pairs. 
 
Outcomes following IVH were evaluated using a matched cohort approach with severe IVH 
being the main exposure. Survival analysis was used to assess risk of mortality, overall and 
within strata of (1) ventilation strategy and (2) eligibility for treatment escalation. Exposure 
time (expressed as child-years) was measured from birth to death/ discharge from the 
neonatal unit. Between-group comparisons were made using Kaplan-Meier curves (log-rank 
test), incidence rate ratios and Cox proportional hazards regression (robust standard errors to 
account for clustering; proportional hazards assumption checked with Schoenfeld residuals). 
Morbidity outcomes were compared between severe and mild IVH using logistic regression 
(robust standard errors). 
 
We estimated that a sample size of 150 (1:1) would have 80% power to detect a 1.6-fold or 
greater mortality hazard ratio among severe versus mild IVH (α=0.05, two-sided). 
 
Ethical Considerations 
Data collection was done by the primary author and all records were kept anonymous. 
Patients’ records on the VON database are structured on number allocations ensuring 
confidentiality. Furthermore, the database is password protected and only accessible to 
designated users involved in data capturing.  
 
The study was approved by the Human Research Ethics Committee, Faculty of Health 




The study population comprised 150 infants (75:75, severe versus mild IVH), of whom 56 
(37%) received non-invasive and 94 (63%), invasive ventilation. 
 
Maternal and Infant Characteristics 
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The median/interquartile range (IQR) gestation at birth was 28 (27-29) weeks. In the non-
invasive ventilation group 28 (50%) of the infants were not considered eligible for escalation 
based on gestation and birth weight, Table 1. Infants who received non-invasive ventilation 
had a lower mean birth weight (880 g versus 1081 g, p<0.0001) and lower median gestation 
at birth (27.9 vs 28.6 weeks, p=0.001) compared to infants who received invasive ventilation. 
 
A greater proportion of infants with severe (compared to mild) IVH received surfactant 
therapy during their admission (81% vs 61%, p=0.007). This result extended across both 
ventilation groups (p=0.03). Other study population characteristics are shown by ventilation 
strategy, in Table 1. 
 
Predictors for severe IVH included gestation at birth (per week increase, OR 0.79 (95% 0.61-
1.03), p=0.08), antenatal steroid use (versus none, OR 0.60 (95% CI 0.32-1.14), p=0.12) and, 
after adjusting for the above, coagulopathy (versus none, aOR 2.36 (95% CI 0.82-6.81), 
p=0.11). The strength of these associations differed within strata of ventilation strategy but 
precision was limited. After adjustment, the strongest predictor for severe IVH was antenatal 




Overall, 61 (41%) of 150 infants died (table 2). Severe IVH was associated with substantially 
increased mortality risk. Figure 1 demonstrates this association within the non-invasive 
ventilation (IRR 5.88, 95% CI 1.85-24.53) and invasive ventilation (IRR 3.96, 95% CI 2.00-
8.26) strata. These results were further reflected in crude and adjusted Cox regression models 
(Table 3). After adjusting for antenatal steroid use, birth weight, coagulopathy and ventilation 
type, the relative hazard for death comparing severe to mild IVH was 4.32 (95% CI 1.99-
9.37, p<0.0001) in non-invasive ventilation and 2.82 (1.47-5.40, p=0.002) in invasive 
ventilation.  
 
In the sub-group of infants not for mechanical ventilation, 11/22 (50%) died: 9/12 (75%) 
infants with severe IVH compared to 2/10 (20%) infants with mild IVH, with an IRR 9.74 
(95% CI 2.02-92.64), as shown in supplemental table 1. Mortality rates and IRR for severe 
versus mild IVH for the sub-group of infants who were eligible for mechanical ventilation are 
summarised in Supplemental Table 2. 
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Overall, the age of death was lower among infants with severe IVH than mild IVH; 68% 
(30/44) of deaths in the severe IVH group demised within the first seven days. Similar 
associations were seen in strata of ventilation strategy (table 2). However, none of these 
results were significant. 
 
Although severity of IVH and presence of coagulopathy during admission were consistently 
the strongest predictors of death (table 3), the effects of birth weight, resuscitation at birth 
and sepsis varied. The protective effects of increasing birth weight were most evident in the 
non-invasive ventilation group (aHR 0.64 (95% CI 0.45-0.91), p=0.01). CPR was protective 
against death in the invasive ventilation group (aHR 0.44 (95% CI 0.20-0.98), p=0.04). 
Sepsis was a significant risk factor for mortality in the non-invasive ventilation group (HR 
4.55 (95% CI 2.25-9.23), p<0.0001). 
 
The commonest primary cause of death overall was blood culture confirmed sepsis (22/61, 
36%). This was followed by pulmonary haemorrhage (16/61, 26%), hyaline membrane 
disease (11/61, 18%), necrotizing enterocolitis (6/61, 10%), extreme prematurity (5/61, 8%) 
and severe hypoxic ischaemic encephalopathy (1/61, 2%). Pulmonary haemorrhage was the 
commonest cause of death in those with severe IVH and blood culture confirmed sepsis in 
those with mild IVH. 
 
Necrotizing enterocolitis (NEC) developed in 16/150 (11%) patients overall. Patients with 
severe IVH and NEC were more likely to have an early death (less than 7 days) close to the 
time of diagnosis of NEC. Mild IVH with NEC was less likely to demise from this. 
 
Morbidity is presented in Table 2. Median length of hospital stay was 62 days (IQR 50-76) 
among survivors overall, with no significant difference by IVH severity. This differed 
compared to time to death/discharge which was considerably shorter in infants with severe 
IVH in each ventilation group. 
 
Periventricular leukomalacia (PVL) was associated with severe IVH in invasive ventilation 
(OR 6.67 (95% CI 1.11-40.17)) in infants who survived through to discharge. Post 
haemorrhagic hydrocephalus (PHH) was not specifically associated with severe or mild IVH.  
Data for ROP were only consistently available for 2016, with one case of clinically 
significant ROP recorded (non-invasive ventilated infant with mild IVH). Among survivors, a 
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higher proportion of infants with severe IVH had prolonged oxygen requirements at 28 days 
(79% vs 38%, p=0.01) (OR 6.11 (95% CI 1.19-31.34), p=0.03) than those with mild IVH. 
 
DISCUSSION 
Preterm birth represents a significant burden in low and middle income countries.[12] 
The study highlighted the role of mechanical ventilation and severe IVH as predictors of 
mortality. Coagulopathy and pulmonary haemorrhage were important contributors to this 
group. 
 
Severely premature infants receive restricted care based on a standardised protocol, in order 
to maintain distributive justice in our setting. The majority of infants received invasive 
ventilation due to reasons other than extreme prematurity. This explains the association 
between a lower mean birth weight and gestation with non-invasive ventilation in our study. 
It also explains why prematurity is an uncommon primary cause of death in the invasive 
ventilation group. 
 
The restriction of invasive ventilation to more mature infants may have influenced certain 
predictors of mortality. Infants receiving invasive ventilation were not protected by an 
increasing birth weight due to resource limitations.[1] In addition, the poor outcomes 
associated with CPR in preterm infants births was not demonstrated.[13] This protective effect 
of CPR in the invasive ventilation group could be explained by the fact that extremely 
preterm infants may not have been offered CPR at birth; hence CPR was associated with the 
provision of invasive ventilation. 
 
Expectedly, overall mortality showed a significant association with severe IVH with no 
difference across ventilation groups.[14] Aly et al.[10] found mechanical ventilation to be an 
important predictor of severe IVH. Our study demonstrated that mechanical ventilation and 
severe IVH (when analysed in the subgroup of infants eligible for escalation) was an 
important predictor of mortality with higher mortality rates per child years and IRR compared 
to non-invasive ventilation. 
 
In patients receiving invasive ventilation with severe IVH, pulmonary haemorrhage was the 
commonest cause of death, with nine out of eleven instances having associated coagulation 
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abnormalities. Coagulopathy was shown to be a poor prognostic factor for mortality overall 
and within ventilation categories. This highlights a vulnerable group in our neonatal unit 
which may benefit from closer monitoring and ICU admission. Current studies suggest that 
coagulopathy screening and correction benefit only a small population of extreme premature 
infants.[15,16]  
 
There was a higher incidence of NEC in mild IVH with the majority surviving, while those 
with severe IVH had a lower incidence of NEC but higher mortality. This can be explained 
by the shorter lifespan and increased mortality rates in infants with severe IVH. Despite the 
temporal relationship between NEC and death, our study did not find it to be predictor of 
mortality. In other studies NEC has not been recognized as an independent risk factor for 
IVH.[3] 
 
Premature infants who survived to discharge had similar lengths of stay in both the invasive 
and non-invasive ventilation groups. Oxygen requirement at 28 days of life was more 
common in infants who received non-invasive ventilation and had severe IVH than those who 
received non-invasive ventilation with mild IVH. This is likely due to the lower birth weight 
and gestational age of infants in this group and their associated comorbidities. However, there 
was no difference in bronchopulmonary dysplasia (assessed at 36 weeks corrected gestational 
age) in either ventilation group in infants with severe or mild IVH. 
 
PHH and PVL are known complications of IVH.[17] This could not be demonstrated in our 
study due to the low numbers with this diagnosis.  
 
Incomplete ROP records could not allow for accurate analysis. Current evidence does not 
show an association between severity of IVH and ROP.[18] 
 
Prophylactic surfactant compared to selective surfactant, in patients with routine CPAP, has 
been researched. The SUPPORT study showed a reduction in severe IVH in patients who 
have received prophylactic surfactant but was not significant.[9] A 2012 Cochrane review 
demonstrated an overall marginal decrease in IVH in patients receiving prophylactic 




Our results reflect the neonatal policy at GSH where surfactant is administered as rescue 
therapy only. Unstable infants are more likely to receive surfactant which may explain the 
high rate of severe IVH and mortality in this group. The timing of surfactant was not 
recorded in relation to the timing of the bleed, so infants may have developed IVH prior to 
surfactant administration. Further studies on surfactant rescue therapy in resource-limited 
settings are needed. 
 
Study limitations and strengths 
The study was limited by its retrospective design, which may increase the risk of bias. The 
use of matched controls resulted in exclusion of some data; the smaller sample size resulted 
in imprecision for some estimates. The effects of mechanical ventilation on severe IVH could 
not be determined for extremely preterm infants because these infants were not offered 
invasive ventilation. Limited data on ROP precluded analysis for this critical outcome. 
Finally, the study was completed in a single tertiary neonatal population, which may limit 
generalizability. However, a major strength of the study is its “real world” setting, which 
provides greater generalizability than data from clinical trials. 
 
CONCLUSION 
Our study demonstrated that mechanical ventilation and severe IVH were important 
predictors of mortality. The commonest cause of death in severe IVH was pulmonary 
haemorrhage with an associated coagulopathy in this group. This provides a useful clinical 
adjunct when determining prognostication and counselling of these patients. 
 
Infants receiving surfactant had a high rate of severe IVH. The high incidence was attributed 
to their instability qualifying them for surfactant therapy. Future studies can focus on the 
relationship between severe IVH and respiratory support, following the administration of 
surfactant. 
 
Understanding outcomes of preterm infants in low and middle income settings may be 
improved by the development and maintenance of quality improvement databases in order to 
facilitate patient management protocols and research in this context. 
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Table 1: Characteristics of study population by ventilation strategy 
 
 Total  
(n=150) 












Maternal characteristics        
Chorio-amnionitis 5 (3%) 1 (4%) 1 (4%) 1.00 2 (4%) 1 (2%) 0.56 
Antenatal steroids 66 (44%) 12 (43%) 19 (68%) 0.06 16 (34%) 19 (40%) 0.52 
Hypertension    
1.00 
  
0.05 No maternal hypertension 112 (75%) 20 (71%) 20 (71%) 40 (85%) 32 (68%) 
Maternal hypertension 38 (25%) 8 (29%) 8 (29%) 7 (15%) 15 (32%) 
Birth characteristics        
Delivery mode    
0.79 
  
0.21 Vaginal 83 (55%) 16 (57%) 17 (61%) 28 (60%) 22 (47%) 
Caesarian section 67 (45%) 12 (43%) 11 (39%) 19 (40%) 25 (53%) 
APGAR score 5 minutes 7 (6-9) 8 (6-9) 8 (7-9) 0.48 7 (6-9) 7 (5-8) 0.84 
Required CPR at birth 32 (21%) 5 (18%) 3 (11%) 0.44 12 (26%) 12 (26%) 1.00 
Hypothermia (<36.5°C) within 
1st hour of birth 
116 (77%) 23 (82%) 22 (79%) 0.74 34 (72%) 37 (79%) 0.47 




 Total  
(n=150) 












Gestation (weeks) 28 (27-29) 27 (27-29) 28 (27-29) 0.14 28 (27-29) 29 (28-30) 0.22 
< 27 weeks 17 (11%) 6 (21%) 6 (21%) 1.00 2 (4%) 3 (6%) 0.65 
Birth weight (grams) 1007 (182) 882 (151) 880 (160) 0.96 1078 (158) 1085 (153) 0.82 
< 800g 16 (11%) 8 (29%) 8 (29%) 1.00 0 0 n/a 
Admission characteristics        
Timing of ventilation    
0.31 
  
0.31 Early (< 48 hours of life) 129 (86%) 27 (96%) 28 (100%) 39 (83%) 35 (74%) 
Late 21 (14%) 1 (4%) 0 8 (17%) 12 (26%) 
Ever received surfactant 107 (71%) 16 (57%) 8 (29%) 0.03 45 (96%) 38 (81%) 0.03 
Age at IVH diagnosis (days) 4 (2-7) 4 (3-7) 7 (3-13) 0.04 3 (2-5) 4 (2-8) 0.36 
Any sepsis during admission 17 (11%) 3 (11%) 0 0.07 4 (9%) 10 (21%) 0.08 
Coagulopathy  21 (14%) 1 (4%) 1 (4%) 1.00 12 (26%) 7 (15%) 0.20 
Necrotizing enterocolitis (NEC) 16 (11%) 2 (7%) 3 (11%) 0.64 2 (4%) 9 (19%) 0.02 
Age at NEC diagnosis (days) 6 (5-21) 3 (1-6) 6 (4-11) 0.37 4 (4-4) 15 (6-30) 0.03 
Numbers are n (column %) except where otherwise indicated; or median (interquartile range, IQR) for non-normally distributed and mean (standard 
deviation, SD) for normally distributed variables. Comparisons (p-values) from Chi2 for categorical, Kruskal-Wallis for non-normally distributed and t-
tests for normally distributed continuous variables 




















Outcomes        
Time to death or discharge 
(overall days in hospital) 
48 (6-69) 38 (7-61) 63 (46-78) 0.002 7 (4-57) 48 (24-73) 0.002 
Combined >27 weeks and > 
800 g 
128 (85%) 16 (57%) 18 (64%) 0.58 47 (100%) 47 (100%) n/a 
Deaths 61 (41%) 14 (50%) 4 (14%) 0.004 30 (64%) 13 (28%) <0.0001 
Died, >27 weeks and 
>800 g 
50/128 (39%) 5/16 (31%) 2/18 (11%) 0.15 30/47 (64%) 13/47 (28%) <0.0001 
Age at death (days) 5 (3-15) 7 (3-15) 16 (9-17) 0.31 4 (3-7) 5 (4-19) 0.28 
Early death (≤7 days) 38/61 (62%) 7/14 (50%) 1/4 (25%) 0.38 23/30 (77%) 7/13 (54%) 0.14 
Survived through to discharge 89 (59%) 14 (50%) 24 (86%) 0.004 17 (36%) 34 (72%) <0.0001 
Length of hospital stay 
(days) 
62 (50-76) 61 (56-64) 70 (55-78) 0.30 59 (50-75) 63 (48-76) 0.75 
PVL 8/89 (9%) 1/14 (7%) 0 0.19 5/17 (29%) 2/34 (6%) 0.02 
PHH 3/89 (3%) 1/14 (7%) 1/24 (4%) 0.69 1/17 (6%) 0 0.15 
Clinically significant ROP* 1/89 (1%) 0 0 n/a 0 1/34 (3%) 0.48 


















days of age† 
Oxygen dependent at 36 
weeks of age‡ 
10/73 (14%) 0/10 2/22 (9%) 0.32 4/13 (31%) 4/28 (14%) 0.22 
Combined end-point: death 
and/or disability§ 
110 (73%) 25 (89%) 13 (46%) 0.001 41 (87%) 31 (66%) 0.01 
Numbers are n (column %) except where otherwise indicated; or median (interquartile range, IQR) for non-normally distributed and mean (standard 
deviation, SD) for normally distributed variables. Comparisons (p-values) from Chi2 for categorical, Kruskal-Wallis for non-normally distributed and t-tests 
for normally distributed continuous variables 
Abbreviations: PVL, peri-ventricular leukomalacia; PHH, post-haemorrhagic hydrocephalus; ROP, retinopathy of prematurity 
*Defined as Grade 3 or greater 
†among those alive and in hospital at 28 days (total N=90; non-invasive, n=39; invasive, n=51)  
‡among those alive and in hospital at 36 weeks’ corrected gestation (total N=76; non-invasive, n=32; invasive, n=44)  





Table 3: Adjusted hazard ratios for mortality, comparing severe to mild intraventricular haemorrhage: stratified by ventilation strategy 
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Required CPR at birth 
2.42 
(0.72-8.10) 













































Abbreviations: aHR, adjusted hazards ratio; CI, confidence interval; IVH, intraventricular haemorrhage; CPR, cardio-pulmonary resuscitation; 








SUPPLEMENTAL TABLE 1: Mortality rates and rate ratios comparing severe to mild intraventricular haemorrhage 
 ≥800 g and ≥27 weeks’ gestation <800 g and/or <27 weeks’ gestation 
 Severe IVH Mild IVH Severe IVH Mild IVH 
Mortality rate per child-year (95% CI) 6.21/cy (4.46-8.64) 1.63/cy (0.98-2.71) 10.40/cy (5.41-20.00) 1.07/cy (0.27-4.27) 





SUPPLEMENTAL TABLE 2: Mortality rates and rate ratios among infants ≥800 g and ≥27 weeks’ gestation: comparing severe to 
mild intraventricular haemorrhage 
 Non-invasive ventilation Invasive ventilation 
 Severe IVH Mild IVH Severe IVH Mild IVH 
Mortality rate per child-year (95% CI) 2.61/cy (1.09-6.27) 0.71/cy (0.18-2.85) 8.06/cy (5.63-11.52) 2.04/cy (1.18-3.51) 







Figure 1: Kaplan-Meier survival curves of infants with severe compared to mild intra-
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